CURRICULUM VITAE

Arie-Lev Gruzman

Born: October, 3, 1970, Gorky (Nizhniy Novgorod), former USSR
Education:

1985 - 1988: First Gorky nurse college (*Summa cum Laude*)
1988 - 1991: Medical school, Pediatric faculty, Gorky Academy for Medicine (study was not finished due to repatriation to Israel)
1993 - 1995: B.Sc., Chemistry, Bar-Ilan University, Ramat-Gan, Israel
1997 - 2003: Ph.D., Medicinal Chemistry and Pharmacology, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Israel Thesis title (*Summa cum Laude*): "Synthesis and study of mechanism of action of novel anti-hyperglycemic compounds for treatment of type 2 diabetes." Supervisors: Prof. Shlomo Sasson and Prof. Jehoshua Katzehendler.
2004 - 2007: Post-Doctoral Research Fellow, Biochemistry, Department of Physiology, Medical School, University of California, San Francisco and Research Institute of Pacific Medical Center at San Francisco, U.S.A. Supervisor: Prof. Vishvanath Lingappa

Positions
2007-2009: Head of the project (Development of new antidiabetic drug), Yissum Technology transfer company of Hebrew University of Jerusalem, Jerusalem.
2009 - 2016: Senior Lecturer, Department of Chemistry, Bar-Ilan University, Ramat-Gan, Israel.
2016-present: Associate Professor, Department of Chemistry, Bar-Ilan University, Ramat-Gan, Israel.

Awards and fellowships

2016. "Outstanding Lecturer". Bar-Ilan University, Ramat-Gan, Israel.

2013. Fellowship for participation in "ALS Drug Discovery" workshop organized by American ALS association, Washington, DC, USA.

2007. Study fellowship, EURO Science Multidisciplinary Program: Prevention and early diagnosis of metabolic syndrome, Summer school for identification of proteins and post-translation modifications by mass spectrometry, de Duve Institute, Brussels, Belgium.

2007. "Faculty of 1000 Biology Award" for paper: "Common molecular signature in SOD1 for both Sporadic and Familial Amyotrophic Lateral Sclerosis. Proc Natl Acad Sci U S A, 2007, 104, 12524-12529 This paper has been selected for "Faculty of 1000 Biology" (http://www.f1000biology.com) "Faculty of 1000 Biology" is an award-winning online service that highlights and evaluates the most 1000 interesting papers in a year (Papers are highlighted on the basis of their scientific merit rather than the journal in which they appear) published in the biological sciences, based on the recommendations of over 2000 of the world's top researchers.

2005. The Best Presentation Award. Prostate Cancer Retreat, UCSF Comprehensive Cancer Centre. San Francisco, USA.

2004. Distinguish PhD dissertation, Faculty of Medicine, The Hebrew University of Jerusalem. Jerusalem, Israel.

2003. The Kaye Award for applied scientific projects. The Industrial Union of Great Britain and The Hebrew University of Jerusalem.

2002. Award for Excellent Tutor. Faculty of Medicine, Hebrew University of Jerusalem. Jerusalem, Israel.

2002. Bern-Schlander Research Award. The Diabetes Research Centre of The Hebrew University of Jerusalem, Jerusalem, Israel.

2001. Award for excellence in study achievements. School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

1999. Ianuka Award for excellent research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

1999. Second Award for excellent research in field of diabetes. The Diabetic Research Centre of The Hebrew University of Jerusalem, Jerusalem, Israel.

1993. Exodus award for outstanding new repatriant students. Bar-Ilan University, Ramat-Gan, Israel.

Supervised students: awards and fellowships

1. Pinchas Zer Aviv, The Best Poster Award, 9th Congress of Israel Association of Medicinal Chemistry, Rehovot, Israel, **2011**.
2. Tamar Getter, "Lev Zion four years PhD fellowship for students from peripheries", **2013-2016.**
3. Shirin Kahremany, "Wolf Prize for outstanding PhD students", **2014.**
4. Sagiv Waintraub, The Best Poster Award in 6th National Student Congress of Organic Chemistry, **2014**.
5. Lena Trifonov, "Schechter Prize" for outstanding master degree students, **2015**.
6. Anna Munder, "D-cure travel grant", for participation (oral presentation) in the 23rd Annual Meeting of Italian Society of Medicinal Chemistry, Solerno, Italy, September, **2015**.
7. Efrat Shtriker, Best Poster Award. "Development of artificial islets", Bio-Organic Retreat of the Chemistry Department, Bar-Ilan University, Acco, January, **2016**.
8. Efrat Shtriker, "Schechter Prize" for outstanding master degree students, **2016**.
9. Ilana Babaev, "TEVA analytical chemistry fellowship" for outstanding ungraduated students, **2016**.
10. Salome Azulay-Ginzburg, "Best poster award", 2nd retreat of Department of Chemistry (bioorganic division), Mitzpe-Ramon, Israel, May, **2017**.
11. Ilana Babaev. 'Best Poster Award", 14th Annual Meeting of the Medicinal Chemistry Section of the Israel Chemical Society (MCS-ICS), Rehovot, Israel, June, **2017**.
12. Laura Levy, "Schechter Prize" for outstanding master degree students, **2018**.
13. Eliav Blum, "Moris Banin Prize" for outstanding PhD students, **2018**.
14. Salome Azulay-Ginzburg, NAAMAT, Edelson Foundation prize for outstanding women researchers in field of chemistry and pharmacology. **2018**.
15. Salome Azulay-Ginzburg, Navon fellowship for PhD students, Israel Ministry of Science, Technology and Space. **2018**.
16. Eliav Blum. The best flash talk presentation. Fighting retinal degenerative diseases with RPE65-inhibitors. 16th Annual Meeting of The Medicinal Chemistry Section of the Israel Chemical Society (MCS-ICS). June, **2019**, Rehovot, Israel.
17. Lena Trifonov, Royall Society of Chemistry, UK. Travel fellowship to VI International Caparica Conference on Analytical Proteomics, Lisbon, Portugal, **2019**.
18. Shirin Kahremany, Postdoctorate fellowship to work in peripheral Israel areas. Israel Ministry of Science, Technology and Space. **2019**.
19. Lena Trifonov, Israel Young Medicinal Chemist Award. **2020**.

Personal research grants

1. European Foundation of Study of Diabetes (EFSD) and D-Cure Young Investigator Awards for Collaborative Diabetes Research between Israel and Europe, **2010-2012** "Rational design, synthesis and mechanism of action of novel antidiabetic ethoxybenzo-thiazol derivatives". ($80.000).
2. DIAB. LTD (France), **2012-2013** "Rational design, synthesis and mechanism of action of novel ethoxythibenzoyl based antidiabetic compounds". ($500.000), with Prof. S. Sasson and Prof. E. Cherasi both from HUJ.
3. Bar-Ilan University Vice President for Research internal grant, **2012**, ($2.000)
4. Israel Ministry of Trade, Labor and Industry (MOTLI), KAMIN program, **2012-2015**, "Novel synthetic chemical chaperones as a basis for Amyotrophic Lateral Sclerosis treatment". ($516.000), with Prof. Daniel Offen, TAU.
5. Galaxy LTD, (Israel/Panama), **2012**, "Development of novel fluorination methods for peptide labeling". ($10.000).
6. D-cure Young Investigation award of Israel Association of Diabetes, "Development of beta cells protecting drugs". **2013**, ($20.000)
7. Bar Ilan University-Rabin Medical Center, **2014**, "Development of new compounds for treatment of Multiple System Atrophy using nasal olfactory stem cells culture". ($20.000), with Prof. Daniel Offen, TAU.
8. ISF. **2014-2018** "Nanotechnology-based development of novel anti-diabetic treatment". ($282.000) with Prof. Jean-Paul Lellouche (BIU).
9. NOFAR, Israel Ministry of Trade, Labor and Industry (MOTLI). **2014-2015,** "Development of novel reagents for generating islets β-cells and enhancing their function based on a clustered nanoformulation of neuroligin-2 mimetics." ($136.000)
10. Bar-Ilan University Vice President for Research internal grant, **2015**, ($13.000)
11. Israel ministry of Trade, Labor and Industry (MOTLI), KAMIN program, **2015-2016**. "Development of novel TLR 4 inhibitors as potential cardioprotective therapeutic agents". ($347.000), with Prof. Edith Hochhauser (Belinson Hospital, TAU).
12. Israel Ministry of Science and Technology (MOST), Scientific and Technological Cooperation between Italy and Israel. **2016-2018**. ALS research. "Development of anti-ALS drugs", with Prof. Gianluca Cestra, (IBPM, Consiglio Nazionale delle Ricerche and University of Rome La Sapienza, Rome, Italy). ($100.000 for two years, for Israeli PI).
13. Israel Scientific Foundation (ISF) grant for the organization of the international workshop "From insulin mimetics until the artificial pancreas- comprehensive approaches in antidiabetic therapy", with Prof. Jean-Paul Lelloushe (BIU). **2017-2018**. ($18.000).
14. Bar-Ilan Rector grant for interdisciplinary research between Bar-Ilan researchers. "Computer-based design and development of novel beta cells pioneering treatment of both types of diabetes." **2017-2018**. ($12.000) with Prof. Jean-Paul Lelloushe, Prof. Hanoch Senderowitz, Prof. Haim Cohen and Dr. Ron Piran.
15. German-Israeli Foundation (GIF), "Understanding of the proteostasis as a basis for novel ALS treatment", **2017-2020** (200.000 Euro) with Prof. Dr. Simon Ebbinghaus Institute of Physical and Theoretical Chemistry, Department of Life Sciences, Technical University Carolo Wilhelmina at Brunswick, Braunschweig, Germany.

16. NOFAR, Israel Ministry of Trade, Labor and Industry (MOTLI). **2018-2019.** A novel phenylchromane derivative increases the rate of glucose uptake in skeletal muscles and augments insulin secretion from pancreatic beta-cells. ($185.000) with Prof. Shlomo Sasson, Hebrew University of Jerusalem. Israel.

17. Israel Ministry of Science and Technology (MOST), Scientific and Technological Cooperation between Vietnam and Israel. **2021-2023**. Inhibiting the copper efflux system in Gram negative microbes by peptidomimetics as a novel approach for developing antibiotics. ($180.000 for Israeli PI), with Dr. Nguyen Tri Nhan, the Faculty of Biology and Biotechnology, University of Science, Vietnam National University in Ho Chi Minh City, Vietnam.

18. "Hava Zingboim" cooperative supported research in antiinflamatory effect of natural compounds. **2021**, ($6.000).

Co-investor research grants

1. ISF. **2010-2014**, "Catecholamine dependent ventricular tachycardia -novel therapies" ($64.000) with Dr. Michael Arad, (Sheba Hospital).
2. ISF. **2010-2014**, Rational design, synthesis and mechanism of action of novel antidiabetic 1,3-dithiane derivatives. ($36.000) with Prof. Shlomo Sasson, (HUJ).
3. Israel Ministry of Trade and Industry (MOTLI), KAMIN program, **2011-2013**, "Development of memory enhancement pill" ($20.000) with Prof. Y. Rosenblum (Haifa University).
4. American Association for Juvenile Diabetes Research Foundation. **2014**, "Preparation of NL-2 based beta-cells enhancers for diabetes treatment" ($10.000) with Prof. Steven Chessler, (UCI, USA)
5. BSF. **2014-2016**, "Development of novel drugs against cystic fibrosis" ($20.000) with Prof. Hanoch Senderowitz (Bar Ilan University).
6. NIH grant. **2016**. Synthesis of chiral β-aminoalcohols as a retinal mimetics ($37.000) With Prof. Krzysztof Palczewski, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

7. Israel Ministry of Industry. **2017-2018**. "KAMIN program". "SAMD9 as a molecular target for the development of the drug candidates for treatment of skin inflammatory diseases". Sub-contractor ($20.000), with Dr. Sarig, Department of Dermatology, Tel Aviv Sourasky Medical Center.

8. Israel Ministry of Industry. **2019-2021**. "KAMIN program". Novel GSK3 inhibitors for treating neurodegenerative disorders. Sub-contractor ($20.000), with Prof. Senderowitz (BIU) and Prof. Hagit Eldar (TAU).

Scientific administrative activity

1. Head of organization committee of 9th congress of Israel Association of Medicinal Chemistry, **2011**, Israel
2. Elected as a Vice-President of Israel Association of Medicinal Chemistry (**2011-2015**)
3. Member of the "Organic, Bioorganic and Medicinal Chemistry panel" in BSF (**2013**).
4. Reviewer of BSF, The National Institute for Biotechnology in the Negev and ISF grants from **2015**.

5. Member of the evaluation board of UK Diabetic Association annual grants. (**2014-current)**
6. Member of the evaluation board of Italian Ministry of Health annual grants (Diabetes). (**2015-current**).
7. Member of the organizing committee of the ASMC'15 (6th International Symposium on Advances in Synthetic and Medicinal Chemistry), Tel-Aviv, Israel, November, (**2015)**.
8. Member of the International board of experts of Polish Academy of Science grants (panel of diabetes research) (**2014-current)**.
9. Head of the organizing committee of 6th National Student Symposium in Organic Chemistry, Bar-Ilan University, (**2014)**.
10. Member of the evaluation board of Czech Republic Health Research Council, annual grants (Diabetes), (**2015-2016).**
11. Israel representative member in European Federation of Medicinal Chemistry (EFMC) EC & Council Meeting, Manchester, UK. 26-29/8/**2016**.
12. Member of an organization committee of 82nd Annual Congress of Israel Chemical Society, **2017**.
13. Head of the organizing committee of international congress "From insulin mimetics until the artificial pancreas- comprehensive approaches in antidiabetic therapy". Ramat-Gan, Israel, **2018**.
14. Member of the evaluation board of Biotechnology and Biological Sciences Research Council, UK, (**2018-2019)**.
15. Member of the scientific board of International Centre of Translational Eye Research, Warsaw, Poland, **2019-current**.
16. Member of the expert panel "Medicinal chemistry" of Polish Academy of Science, Krakow, Poland, **2019-current.**
17. The Field Editor (Medicinal Chemistry) of "Pharmacological Reports", **2020-current.**

Reviewer for journals:

"Journal of Medicinal Chemistry Letters", "The Journal of Pharmacology and Pharmacy", "Royal Pharmaceutical Society of UK", "Medicinal Chemistry", "Molecules", "Future Medicinal Chemistry", "Medicinal Chemistry Communications" "Journal of Basic and Clinical Physiology and Pharmacology", "European Journal of Medicinal Chemistry", "Bioorganic and Medicinal Chemistry Letters", "Archives of Physiology and Biochemistry", "International Journal of Molecular Sciences", "Combinatorial Chemistry & High Throughput Screening", "Mini-reviews in Medicinal Chemistry", "Current Diabetes Review", "Molecular Biosystems", "Journal of Medicinal Chemistry", "Food and Function", "ChemMedChem","Engineering", Biochemical. Pharmacology", "Helvetica Chimica Acta", "Zeitschrift für anorganische und allgemeine Chemie", "Journal of Biomedical Optics", "Current Organic Chemistry", "Journal of Inorganic Biological Chemistry", "Chemistry Select", "Advances in Medical Sciences", "Current Bioactive Compounds", "ACS Chemical Neuroscience", "Bioorganic and Medicinal Chemistry", "Letters of Drug Design and Development", "ACS Applied Materials and Interfaces", "PLOS1", "Current Medicinal Chemistry", "Inorganic chemistry", "Biomedical and Environmental Sciences", "Mendeleev Communications",

"Antioxidants", "Journal of Cancer Therapy", "Polycyclic Aromatic Compounds", "*Journal of Photochemistry & Photobiology, B: Biology", "Science Translational Medicine", "Molecular Genetic and Metabolism". "Bioconjugate Chemistry", "Matirials", "Molecular Biology Reports".*

Bar-Ilan University Administrative activity

1. **2017**. Member of the committee for the "outstanding lecturer award"
2. **2020-2021**. Member of the committee for the "outstanding lecturer award"

Department of Chemistry Administrative activity

3. **2011-2013**. Member of the "culture events" committee of the department.
4. **2013**. Member of the department committee for organization the chemistry study for ultraorthodox Jewish community.
5. **2016**. Bio-Organic Retreat of the Chemistry Department, Bar-Ilan University, Acco. Member of organizing committee.
6. **2016**. Member of the department committee for establishing a mechanism of rotation in master degree studies.
7. **2017**. Head of the committee for the establishing of the National Medicinal Chemistry Teaching Laboratory for high school students (biotechnology) on the budget of the Ministry of Education.
8. **2019.** Head of the committee for the establishing a combine degree in chemistry/pharmacy between Bar-Ilan University and Hebrew University of Jerusalem.
9. **2021**. Academic adviser for the second degree students (the pathway without the thesis)

Industry consultant activity

1. 2005-2007. Development of inhibitors of the virus capsid assembly. Prosetta corporation, San Francisco, USA.
2. 2010-2011. Development of new synthetic route for sialic acid derivatives. VacciGuard LTD, Nes-Ziona, Israel.
3. 2013-2015. Development anticancer drugs, Promining therapeutics LTD, Nes-Ziona, Israel.
4. 2014-2015. Development of "mutations stopper". NOVITERO LTD, Petach-Tikva, Israel.
5. 2014-2018. All related to medicinal chemistry projects. The National Institute for Biotechnology in the Negev Ltd., Beer-Sheva, Israel.
6. 2015-present. All drug development projects in Sourasky Medical Center, Tel-Aviv.
7. 2015-present. Development non-toxic for human pesticides. Evogene LTD, Rehovot, Israel.
8. 2019-present. All drug development projects in RAMBAM MedTech Ltd., Technology Transfer company.

Teaching duty

1. "Spectroscopy and structural determination" for 2rd year B.Sc. students (84-237), **2010-2017**.
2. "Pharmacology and metabolism of drugs" for 3rd year B.Sc. students (84-366), **2010-2017.**
3. "Advanced organic chemistry laboratory practice" for 3rd year B.Sc. students (84-305), **2010-current.**
4. "Kashrut and chemistry", Department for study of science, halacha and education (77-992-21), **2015-current**.
5. "Medicinal chemistry" 3rd year B.Sc. (84-361), **2018-current**.
6. "Molecular pharmacology as a basis for drug development" (84-845-01) for M.Sc. and PhD students. **2015-current.**
7. "Biochemistry" 3rd year B.Sc. (84-319), **2020-2021**.
8. "Advanced organic chemistry" for M.Sc. and PhD students. (84-311), **2019-current**.
9. "Organic Chemistry", 2nd year B.Sc. starting from **2022.**

Dozens of lectures were given on volunteering basis for "GIL ZAHAV" education program, upgrading qualification studies for biology and chemistry teachers, students of high schools, students from peripheral areal of Israel, "Science in the Bar". The average mark (according to survey) for 5 years of teaching of two frontal courses is **4.75**.

*The maximal mark was **4.97** (out of maximal 5.0) for teaching the course number 84-237 in 2014.

Patents

1. Lingappa, V.; Liu, J.; **Gruzman, A**. (**2007**). Biomarkers for ALS. WO2007067900A2 Prosetta Corporation.

2. Sasson, S.; Cerasi, E.; **Gruzman, A**.; Katzhendler, (**2010**). Novel pentose derivatives as anti-hyperglycemic drugs. EP US DK EP 1554299B1 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

3. Sasson, S.; Cerasi, E.; **Gruzman, A**,; Meltzer-Matz, E. (**2016**). Compounds and compositions for use in augmentation of glucose. WO EP US US9409904B2 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd

4. Munder, A., Chessler, S., Lellouche, J-P., **Gruzman A**. (**2018**). "Compositions and Methods for Enhancing Beta Cell Maturation, Health and Function." No. WO2018106982A1 The Regents Of The University Of California.

5. Shoshan-Barmatz V. and **Gruzman A**. (**2018**). "Novel piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunctions". WO EP US CN AU IL US20180118700A1. The National Institute for Biotechnology in the Negev Ltd. *This patent was licensing to the company: "Abarceo Pharma"*

6. Shoshan-Barmatz V and **Gruzman A**. (**2018**). Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors. US US20180078548A1. The National Institute for Biotechnology in the Negev Ltd.

7. **Gruzman A**, Getter T, Imhof B, Bradfield P, Matthes M, Senderowitz H. (**2019**). "Novel barbituric acid based leucocyte transmigration inhibitors as drug candidates for treating inflammatory diseases, autoimmune diseases and cancer". WO2019043706A1. *This patent was licensing by BIRAD to the company: "AltA-ZuZ".*

8. Hochhauser E, **Gruzman A**. and Trifonov L. (**2019**). "Toll-like receptor 4 (TLR4) inhibitors and use thereof", U.S. Provisional Patent Application, PCT/IB2019/054258. *This patent was licensing by "MOR" to the company: "Elios".*

9. Las G, **Gruzman A**, Cerqueira F, Shirihai O (**2019**). "Novel benzothiophene derivatives and use thereof in stimulating mitochondrial turnover", U.S. Provisional Patent Application No. 62/677,076

10. **Gruzman A**., Senderowitz H., Kahremany S., Cohen G. (**2020**) "New Substituted benzylidene-amino-phenyl-pyrrolidine-3-carboxylic acid derivatives and Uses Thereof" US Provisional Patent Application No. 62/813,052

Book chapters

1. **Gruzman, A**. "Solutions for pharmaceutical license examines in Israel, USA, and Canada" Editor: Ludensky S., Kriger Research & Education Center. Tel-Aviv New York, Toronto, Frankfurt, **1999**.

2. **Gruzman, A**.; Ermolaev, G. "Supplementary material: Solutions for pharmaceutical license examines in Israel, USA and Canada" Editor: Ludensky S., Kriger Research & Education Center. Tel-Aviv, New-York, Toronto, Frankfurt. **2000**

Lectures in International Conferences

1. Alpert, E.; **Gruzman A**. COX-2 inhibitors increase the rate of hexose transport in L-6 skeletal muscle cells. 3rd World congress on prevention of diabetes and its complication. Hong Kong, China**,** September, **2002**
2. Sasson S., and **Gruzman A**. Development novel antihyperglycemic drugs. 39th Annual meeting of European association for the study of diabetes. Paris, France, May, **2003**
3. ***Gruzman A.** Development of novel antihyperglycemic drugs for the treatment of diabetes. Meeting of the Diabetes Research Center of Hebrew University of Jerusalem, Jerusalem, Israel, June, **2003**
4. Sasson, S. **Gruzman A.** Effects of the antioxidant nitroxide on energy metabolism in vascular endothelial cells under hyperglycemic conditions. The 8th Meeting of the European Association for the Study of Diabetes (EASD) Study Group on "Hypertension in Diabetes" (HID). Oegstgeest, The Netherlands. May, **2003**
5. **Gruzman A** and Sasson, S. Novel antihyperglycemic compounds that augment glucose transport in skeletal muscles in non-insulin dependent manner. The 21st Annual Meeting of The Israel Diabetes Association. Tel Aviv, Israel. May **2004**

6. William L. Wood, **Gruzman A**. Identification of a biomarker for ALS by nanoelectrospray. The 34th Northeast Regional Meeting of American Chemical Society. Binghamton, New York, USA. October **2006**

7. **Gruzman, A**.; Sasson S. In vivo antidiabetic activity of new D-xylose lipophilic derivatives. The 26th Annual Meeting of the Israel Diabetes Association. Tel Aviv, Israel, **2009**.

As a Principal Investigator at Bar-Ilan University

8. ***Gruzman, A.** Development of new antidiabetic drugs. Advanced Science in Organic Chemistry, The Russian Academy of Science, Mishor, Crimea, Ukraine. June, **2010**.

9. ***Gruzman A.** Development of new drugs. Saxony-Israel new partnership workshop. Medical school, University of Dresden, Dresden, Germany, July, **2010**

10. Getter T., Zaks I., Green O., ***Gruzman A**. Novel Synthetic Chemical Chaperones as a New Basis for Amyotrophic Lateral Sclerosis (ALS) Treatment. 29th Cyprus-Camerino-Noordwijkerhout Trends in Drug Research Medicinal Chemistry, European Federation of Medicinal Chemistry, Limassol, Cyprus, October, **2011**

11. Meltzer-Mats E., **Gruzman A.** Ethoxybenzo-Thiazol Derivatives as Bifunctional Antihyperglycemic compounds. 11th Meeting of Medicinal Chemistry Section of Israel Chemical Society, Rehovot, Israel, June, **2013**

12. Getter T., Zaks I., Green O., **Gruzman A**. Novel Synthetic Chemical Chaperones as a New Basis for Amyotrophic Lateral Sclerosis (ALS) Treatment. International Symposium on Advances in Synthetic and Medicinal Chemistry, European Federation of Medicinal Chemistry, Moscow, Russia, June, **2013**

13. Meltzer-Mats E.,***Gruzman A**. Ethoxybenzo-Thiazol Derivatives as Bifunctional Antihyperglycemic compounds. VIIIth Joint Meeting of Polish, Czech, Slovak, German and Italian organizations of Medicinal Chemistry, European Federation of Medicinal Chemistry, Lublin, Poland, July, **2013**

14. Getter T. and **Gruzman A**. Novel Synthetic Chemical Chaperones as a New Basis for Amyotrophic Lateral Sclerosis (ALS) Treatment. Frontiers in Medicinal Chemistry, Tübingen, Germany, March, **2014**

15. Meltzer-Mats E., Rosentul N., ***Gruzman A**. Poly-aromatic heterocyclic AMPK activators: the new platform for developing of bi-functional drugs against type two diabetes. 32nd Cyprus-Noordwijkerhout-Camerino Symposium-Trends in Drug Research. European Federation of Medicinal Chemistry, Limassol, Cyprus, May, **2014**

16. Getter T., Zaks I., ***Gruzman A.** Novel Synthetic Chemical Chaperones as a New Basis for Amyotrophic Lateral Sclerosis (ALS). 12th Meeting of Medicinal Chemistry Section of Israel Chemical Society Rehovot, Israel, June, **2014**

17. Zer Aviv P., Shokhen M., **Gruzman A.** Rational design and synthesis of new peptidomimetic drug candidates for treatment of prostate cancer. IUPAC 20th International Conference on Organic Synthesis, Budapest, Hungary, June, **2014**.

18. Getter T., Zaks I., ***Gruzman A.** Novel Synthetic Chemical Chaperones as a New Basis for Amyotrophic Lateral Sclerosis (ALS). ISRALS annual conference, Rehovot, Israel, September, **2014.**

19. Getter T., Zaks I., ***Gruzman A.** Novel Synthetic Chemical Chaperones as a New Basis for Amyotrophic Lateral Sclerosis (ALS). Annual Symposium of Israel Association of Neurology. Kfar-Blum, Israel, November, **2014.**

20. Getter T., Zaks I., **Gruzman A.** Novel Synthetic Chemical Chaperones as a New Basis for Amyotrophic Lateral Sclerosis (ALS). 25th International Symposium on ALS/Motor Neuron Diseases Brussel, Belgium, December, **2014.**

21. Munder A., Shtriker E., Rosentul N., *__**Gruzman A**__. Workshop on diabesity: THE MEDICAL CHALLENGE OF THE 21st CENTURY. The Italian-Israeli Forum on Medicine and Health. Jerusalem, Israel, June, **2015**.

22. Getter T., Zaks I., __**Gruzman A**__. Novel Synthetic Chemical Chaperones as a New Basis for Amyotrophic Lateral Sclerosis (ALS). Spanish-Italian Medicinal Chemistry Congress (SIMCC). Barcelona, Spain, July, **2015**.

23. Munder A., Israel L., Kahremany S., Zhang C., Chessler S., Lellouche JP., **Gruzman A**. Mimicking Neuroligin-2 Functions in β-cells by Functionalized Nanoparticles as a Novel Approach for Antidiabetic Therapy. The 23rd Annual Meeting of Italian Society of Medicinal chemistry, Solerno, Italy, September, **2015**.

24. Zer-Aviv P., Shubely M., Moskovitz Y., Shokhen M., __**Gruzman A**__. Rational Design and Synthesis of Novel Peptidomimetic Drug Candidate for Prostate Cancer Treatment. 10th Asian Federation of Medicinal Chemistry Symposium. Jeju, Korea, October, **2015**.

25. __***Gruzman A**__. Rational Design and Synthesis of Novel Peptidomimetic Drug Candidate for Prostate Cancer Treatment. 81st Annual meeting of Israel Chemical Society. Tel-Aviv, Israel, February, **2016**.

26. Meltzer-Mats E., Rosentul N., Sasson S.,*__**Gruzman** A__. Poly-aromatic heterocyclic AMPK activators: the new platform for developing of bifunctional drugs against type two diabetes. 22nd Russian National Congress "Man and Drug". Russian Academy of Science. Moscow, Russia, April, **2016**.

27. __***Gruzman A**__. Development of artificial pancreatic islets. 6th Annual World Congress of Nano Science and Technology. Singapore, October, **2016**.

28. __***Gruzman A**__. and Getter T. "Preparation of fluorinated version of a drug candidates for pharmacokinetic studies". 2nd Cararica Conference on Samples Treatment. Caraica, Portugal, December, **2016**.

29. Levy L., Getter T., **Gruzman A.** Development of the leucocytes rolling blockers.14th Annual Meeting of The Medicinal Chemistry Section of the Israel Chemical Society (MCS-ICS), Rehovot, Israel, June, **2017**.

30. Shubely M., Dhanoop M., Shokhen M., Blank M., **Gruzman A**. "Development of novel drug candidate against prostate cancer." 10th Joint Meeting of Medicinal Chemistry Associations of Austria, Croatia, Czech Republic, Greece, Hungary, Italy, Poland, Slovakia and Slovenia. Dubrovnik, Croatia, July, **2017.**

31. __**Gruzman A**__ and Shoshan-Barmatz V. "Novel phenylpiperazine derivatives targeting mitochondria as a new treatment of neurodegenerative diseases." 11th Asian Federation of Medicinal Chemistry Symposium, Melbourne, Australia, July, **2017**.

32. __**Gruzman A**__ and Getter T. "The novel pyrimidine-based total inhibitors of the monocyte rolling" 42nd Congress of The Federation of the European Biochemical Societies (FEBS). Jerusalem, Israel. September, **2017**.

33. __***Gruzman A**__. "Mimicking Neuroligin-2 (NL-2) Functions in β-Cells as a Novel Approach for Antidiabetic Therapy". Excellence RESOLV series, the cluster of seminars about novel approaches in comprehensive science. October, **2017**, Bochum, Germany.

As an Associate Professor

34. __***Gruzman A**__. "The chemistry of peptidomimetics". Four lectures (master class) International Summer School for PhD students. "Medicinal Chemistry and Structural Biology: Drug-Target interactions" June, **2018**, Lublin, Poland.

35. Getter T, Margalit R, Alpert G, Zilber S, Bradfield P, Kumar A, Kahremany S, Senderowitz H, Lahav R, Matthes T, Imhof B, **Gruzman A**. "Development of the novel barbituric acid-based total inhibitors of leukocyte transmigration." XXVth European Federation of Medicinal Chemistry congress, September, **2018**, Ljubljana, Slovenia. Flash oral presentation.

36. Korshin E, Rozentul N, Avrahami Y, Shubely M, Levy L, Munder A, Cohen G, Cerasi E, Sasson S, **Gruzman A**. A potent antihyperglycemic cyclic dithioacetals of 2-aryl-6-formylchromanes: synthesis, in vitro and in vivo evaluation. The 28th European Colloquium on Heterocyclic Chemistry, September, **2018**, Lecce, Italy.

37. Getter T, Margalit R, Alpert G, Zilber S, Bradfield P, Kumar A, Kahremany S, Senderowitz H, Lahav R, Matthes T, Imhof B, ***Gruzman A**. "The total inhibition of the leukocyte transmigration". IXth annual congress of Polish Medicinal Chemistry Society, September, **2018**, Lublin, Poland. Plenary lecture.

38. Getter T, Margalit R, Alpert G, Zilber S, Bradfield P, Kumar A, Kahremany S, Senderowitz H, Lahav R, Matthes T, Imhof B, **Gruzman A**. Novel barbituric acid-based total inhibitor of leukocyte transmigration" the 6th International Bio-Medical Congress (IMBMC), November, **2018**, Nicosia, Cyprus.

39. Azulay- Ginsburg S., **Gruzman A.** Development of novel chemical chaperones for the treatment of misfolded proteins related diseases. 26th Young Research Fellows Meeting of the French Medicinal Chemistry Society (SCT). February, **2019**, Paris, France.

40. Trifonov L., Korshin E., Zhenin M., Senderowitz H., Hochhauser E., **Gruzman A.** "Structurally simple, readily available peptidomimetic 1-Benzyl-5-methyl-4-(n-octylamino)pyrimidin-2(1H)-one exhibited efficient cardioprotection in a myocardial ischemia (MI) mouse model" 2nd Molecules Medicinal Chemistry Symposium (MMCS): Facing Novel Challenges in Drug Discovery. May, **2019**, Barcelona, Spain.

41. Munder A., Kahremany S., **Gruzman A**. Mimicking Neuroligin-2 (NL-2) Function in Pancreatic β-cells by Nanocomposites as a Novel Approach for Antidiabetic Therapy. XXXVII Biennial Meeting of the Spanish Royal Society of Chemistry, May, **2019**, Donostia-San Sebastián, Spain.

42. Korshin E., Trifonov L., Zhenin M., Senderowitz H., Hochhauser E., **Gruzman A.** "Structurally simple, readily available peptidomimetic 1-Benzyl-5-methyl-4-(n-octylamino)pyrimidin-2(1H)-one exhibited efficient cardioprotection in a myocardial ischemia (MI) mouse model" Bioheterocycles: XVIII International Conference on Heterocycles in Bioorganic Chemistry, June, **2019**, Ghent, Belgium.

43. Blum E., Jianye Z., Palczewski K., ***Gruzman A**. Fighting retinal degenerative diseases with RPE65-inhibitors. 2nd CREATE Symposium: Physical Chemistry in Biological Systems – towards comprehensive research on eye and vision, June, **2019**, Warsaw, Poland.

44. Blum E., Jianye Z., Palczewski K., **Gruzman A.** Fighting retinal degenerative diseases with RPE65-inhibitors. 16th Annual Meeting of The Medicinal Chemistry Section of the Israel Chemical Society (MCS-ICS). June, 2019, Rehovot, Israel, Flash oral presentation.

45. Trifonov L., Korshin E., Zhenin M., Senderowitz H., Hochhauser E., **Gruzman A.** "Structurally simple, readily available peptidomimetic 1-Benzyl-5-methyl-4-(n-octylamino)pyrimidin-2(1H)-one exhibited efficient cardioprotection in a myocardial ischemia (MI) mouse model" 16th Annual Meeting of The Medicinal Chemistry Section of the Israel Chemical Society (MCS-ICS). June, **2019**, Rehovot, Israel, Flash oral presentation.

46. Trifinov L. and *__Gruzman A__. "Determination of TLR-4 inhibitor mode of action by MS". The VI—International Caparica Congress on Analytical Proteomics—ICAP, July, **2019**, Lisbon, Portugal.

47. Munder A. and **Gruzman A.** Mimicking Neuroligin-2 (NL-2) Function in Pancreatic β-cells by Nanocomposites as a Novel Approach for Antidiabetic Therapy. 11th International Dendrimer Symposium, July, **2019**, Funchal, Madeira Island, Portugal.

48. ***Gruzman A**. Chemistry of peptidomimetics. 6th Prague-Weizmann Summer School on Drug Discovery, September, **2019**, Prague, Czech Republic.

49. ***Gruzman A.**, Getter T., Margalit R., Kahremany S., Lahav R., Zilber S., Bradfield P., Imhof B., Alpert E. Novel in vivo active inhibitors of leukocyte transendothelial migration. 2nd Conference "Chemistry of Bioactive Compounds, ChemBioActiv", October, **2019**, Saratov, Russia. (Plenary lecture)

50. ***Gruzman A**. Novel in vivo active inhibitors of leukocyte transendothelial migration. 1st Israel Open-Screen workshop. November, Rehovot, **2019**, Israel.

51. Getter T, Margalit R, Zilber S, Kahremany S, Hazanov N, Levy L, Blum E, Lahav R, Senderowitz H, Bradfield P, Imhof B, Alpert E and **Gruzman A**. Development of Novel Drug Candidate for Treatment of Autoimmune Diseases based on the Inhibition of Leukocyte Transendothelial Migration. The 18th Asian Chemical Congress and The 20th General Assembly of the Federation of Asian Chemical Societies, December, **2019**, Taipei, Taiwan.

52. Munder A, Shtriker E, **Gruzman A**. Mimicking Neuroligin-2 (NL-2) Function in Pancreatic β-cells by Nanocomposites as a Novel Approach for Antidiabetic Therapy. 9th International Conference on Chemical and Process Engineering (ICCPE 2020), May, **2020**, Moscow, Russia. (The congress was transferred to the on-line mode due to COVID-19 pandemic).

53. *Trifonov L., Korshin E., Zhenin M., Senderowitz H., Hochhauser E., **Gruzman A.** "Structurally simple, readily available peptidomimetic 1-Benzyl-5-methyl-4-(n-octylamino)pyrimidin-2(1H)-one exhibited efficient cardioprotection in a myocardial ischemia (MI) mouse model", 7th EFMC (European Federation of Medicinal Chemistry) Young Medicinal Chemist Symposium, September, **2020**, Basel, Switzerland. The congress was transferred to the on-line mode due to COVID-19 pandemic).

54. Levy L, Getter T, Margalit R, Zilber S, Kahremany S, Hazanov N, Blum E, Lahav R, Senderowitz H, Bradfield P, Imhof B, Alpert E and **Gruzman A**. Development of the novel inhibitor of the leukocyte transmigration as a drug candidate for the universal treatment of auto-immune diseases. 12th Autoimmunity Congress, December, **2020**, Athens, Greece. The congress was transferred to the on-line mode due to COVID-19 pandemic).

Underlined the person's name who actually delivered the lecture.

**Invited lecture. Without star: the presentation was selected for a lecture from the submitted abstracts.*